Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect from Today
Source: PIB (Press Information Bureau) · Read the original ↗
Summary
- NPPA capped trade margins on the MRP of 137 anti-cancer drugs. It acted on the recommendations of a DGHS (Ministry of Health & Family Welfare) Expert Committee, with the notification dated 17 October 2026.
- The revised MRPs took effect on 9 November 2026.
- By 8 November, 85 companies had reported revised MRPs for 1,364 formulations covering 121 drugs.
- The government expects consumer savings of ₹3,540.38 crore a year.
Key facts for Prelims
- NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- The expert committee that recommended the 137 drugs was constituted by the Directorate General of Health Services (Ministry of Health & Family Welfare).
- The DPCO 2013 is issued under the Essential Commodities Act, 1955. Para 19 permits price fixation in public interest. TMR is the mechanism used.
- Scheduled drugs (NLEM-based First Schedule) get ceiling prices. Non-scheduled drugs are subject to a 10% annual MRP-rise limit.
- Consumer tools: the Pharma Sahi Daam mobile app and the NPPA website (nppa.gov.in). Grievances go to the Pharma Jan Samadhan portal. NPPA helpline: 1800-111-255.
- No chemist or hospital pharmacy can charge above the revised MRP printed on the pack.
- Related institutions: NLEM (Health Ministry), DGHS, DPCO 2013, NPPP 2012.
Data and details
- 137 anti-cancer drugs are covered by the trade-margin cap. The notification is dated 17 October 2026, and revised MRPs are effective 9 November 2026.
- As on 8 November 2026, 85 pharmaceutical companies reported revised MRPs for 1,364 formulations covering 121 drugs.
- 679 brands reported price reductions of more than 50%.
- The highest reported reduction is 96.45%.
- Estimated annual consumer savings are ₹3,540.38 crore.
- The company reporting is partial (as on 8 November). The count of 1,364 formulations and 121 drugs is lower than the 137 drugs notified.
Static–dynamic linkage
- India regulates drug prices through the Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, 1955.
- "Scheduled" drugs are those in the NLEM-based First Schedule. They get a ceiling price.
- "Non-scheduled" drugs are priced freely by the manufacturer, subject to a 10% annual MRP-rise limit.
- A Trade Margin Rationalisation (TMR) cap is a different tool. It limits the markup between the price to the retailer and the MRP.
- This is how the State reaches high-markup drugs that sit outside price control, without fixing manufacturer prices.
- The link to public policy is out-of-pocket expenditure on health, which is the major driver of impoverishment. Cancer care is a leading example.
Syllabus mapping: GS2 – Governance/Social Justice: Health; regulatory bodies | GS3 – Economy: Pricing regulation, pharma sector | Prelims – Economy/Polity (statutory and regulatory bodies)
Background primer
National Pharmaceutical Pricing Authority (NPPA)
- What it is:
- an independent body of experts and regulator for drug pricing. It is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
- Founded:
- constituted by a Government of India Resolution dated 29 August 1997. The aim was to have a dedicated body to fix, revise and enforce prices of controlled drugs, because earlier price orders (DPCOs) lacked a dedicated monitoring and enforcement authority.
- Members:
- headed by a Chairperson; detailed composition not confirmed from a trusted source.
Drugs (Prices Control) Order, 2013
- What it is:
- the price-control order notified on 15 May 2013 under the Essential Commodities Act, 1955.
Additional context
-
Legal route. The 2026 cap was reported as 30% of MRP (excluding GST) under Para 19 of DPCO 2013. Manufacturers had to inform NPPA of revised prices within seven days of the notification.
-
Earlier pilot. The measure builds on NPPA's February 2019 pilot, which capped margins on 42 non-scheduled anti-cancer drugs. It cut the MRPs of 526 brands by up to 90%, with reported savings of about ₹984 crore a year.
-
Why non-scheduled drugs. NPPA has said that regulating scheduled drugs covers only about 16–17% of the pharma market. It has said arbitrary pricing through high markups persists in the non-scheduled segment.
-
Supreme Court. A GKToday explainer says the Supreme Court had flagged cases where the MRP of cancer medicines was up to ten times the price to retailers.
-
Permanence. The Parliamentary Standing Committee on Chemicals and Fertilizers reported on 6 August 2026. It noted that TMR has been used only as a pilot for certain anti-cancer medicines and COVID-19 devices, and that there is no timeframe to integrate a permanent TMR framework into DPCO 2013.
Mains dimensions
- Health economics. Out-of-pocket spending on medicines pushes households into poverty. Targeting cancer drugs, where treatment is long, expensive and catastrophic, responds to a high-burden area.
- Regulatory design. TMR is a lighter tool than full price control. It limits distributor and retailer markups instead of fixing manufacturer prices. The 2019 pilot (42 drugs) has now been widened to 137 drugs.
- Scale of the effect. More than half of the reporting brands show a cut of over 50%, and the top cut is 96.45%. This suggests very large trade margins were embedded in the earlier MRPs.
- Enforcement and awareness. The framework depends on price display, the Pharma Sahi Daam app, the Pharma Jan Samadhan grievance portal and a toll-free helpline. The notice that no chemist or hospital pharmacy can exceed the revised MRP places liability on the retail end of the chain.
- Institutional and legal limits. The measure rests on the "extraordinary circumstances" power in Para 19, not a standing TMR provision. A permanent framework and wider data coverage remain open issues.
- Federal and administrative linkage. The Health Ministry's DGHS expert committee recommends and the Chemicals & Fertilizers Ministry's NPPA implements. This is a case of inter-ministerial coordination.
- Way forward. Embed TMR in DPCO and extend it to other chronic-disease drugs. Improve price data and monitoring. Pair it with generic promotion (Jan Aushadhi) and procurement reform.
Possible Mains question
**GS2, 15 marks:** "Out-of-pocket expenditure on medicines remains a major cause of impoverishment in India. Examine the regulatory tools available for drug price control and assess the role of Trade Margin Rationalisation in making cancer treatment affordable."
Related topics
- National List of Essential Medicines (NLEM) and the DPCO Schedule-I
- Essential Commodities Act, 1955
- National Pharmaceutical Pricing Policy 2012
- Jan Aushadhi (PMBJP) and Ayushman Bharat PM-JAY
- Out-of-pocket expenditure and National Health Policy 2017
- Parliamentary Standing Committees
Topics: GS2
All current affairs of 9 November 2026 → · UPSC Current Affairs